The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
The company is confident of addressing all the observations within the stipulated time
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Investment is additive to KKR’s existing health care growth strategy
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Subscribe To Our Newsletter & Stay Updated
